Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
apoptotic cells can be observed by flow cytometry by measuring changes in light scattering
which presents advantages for drug development targeting this receptor
Kit Components:A copy of pre coated 96 well plate
Tissue homogenate:The tissues were washed with pre-cooled PBS (0
NDRG1 is a potent
ActRIIA Enzyme Activity Inhibitor Screening Kit Isotype control apoptotic cells can be observedProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving
US$ 2345.00
US$ 6975.00
US$ 3445.00
US$ 3749.50
US$ 7245.00
US$ 8975.00
US$ 6750.00
US$ 5245.00
US$ 4495.00
US$ 4495.00
US$ 5995.00
US$ 9450.00
US$ 2745.00
US$ 3495.00
US$ 12999.50
US$ 4495.00
US$ 4995.00
US$ 3695.00